APRICUS AND TAKEDA ENTER INTO LICENCE AGREEMENT TO MARKET VITAROS IN THE UK
Apricus and Takeda have jointly announced that they have entered into
an exclusive licence agreement to market Vitaros, a treatment for
erectile dysfunction, in the UK, RTTNews reports.
Takeda will pay NexMed, a wholly owned subsidiary of Apricus
Biosciences, an undisclosed upfront payment, and milestone payments of
up to EUR35 million. Vitaros is a topically delivered formulation of
alprostadil, a vasodilator, supplied in a single dose dispenser, for
the treatment of erectile dysfunction.
The marketing authorisation application for Vitaros was accepted by
the European Medicines Agency for review in June 2011 and the licence
is anticipated in 2013. Vitaros has received marketing authorisation
in Canada and is being marketed by Abbott. In the US, commercial
rights to Vitaros have been licensed to Warner Chilcott. Agreements
have also been signed with Sandoz-Novartis in Germany, Bracco in
Italy, Elis Pharma in certain Middle East, and Gulf countries, and
Neopharm in Israel.